Literature DB >> 22305344

Rebound symptoms following battery depletion in the NIH OCD DBS cohort: clinical and reimbursement issues.

A K Vora1, H Ward, K D Foote, W K Goodman, M S Okun.   

Abstract

OBJECTIVE: Deep brain stimulation (DBS) is a promising treatment for medication refractory obsessive compulsive disorder (OCD); however, there may be neuropsychiatric symptoms from unintended battery failure.
BACKGROUND: Previous studies indicated rebound symptoms from impulse generator (IPG) failure in Parkinson's disease, dystonia, and essential tremor. Unique to OCD is that battery failure may precipitate neuropsychiatric symptoms rather than motor symptoms.
METHODS: Six patients with medication refractory OCD received implants as part of the previously reported National Institutional Health (NIH) DBS cohort. All available clinical data and adverse event data was reviewed.
RESULTS: The average age of cohort was 42.2 years (30-59 years), and the average baseline Y-BOCS score was 33.8 (31-38). All six subjects were observed to have increased OCD symptomatology during IPG failure; however, Y-BOCS scores remained less than pretreatment range, in five subjects. One of the subjects had a Y-BOCS score greater than pretreatment during the period of IPG failure. In addition, Y-BOCS scores improved back to baseline after IPG replacement in five subjects. Other symptoms potentially related to battery failure included: suicidality (n = 1), mood disturbance (n = 2), panic attacks (n = 1), fatigue (n = 2), and a restless sensation in the arms and legs (n = 1). A small number of subjects reported no side effects associated with IPG failure because of preemptive replacement (n = 2).
CONCLUSIONS: This is a preliminary case series detailing the side effects resulting from IPG failure during OCD DBS. Preemptive battery replacement was an effective strategy for avoiding these issues, and timeliness in insurance reimbursement may be considered in the future. Additionally the use of rechargeable batteries may also help this issue. CLINICAL TRIAL REGISTRATION NUMBER: NCT00057603.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22305344     DOI: 10.1016/j.brs.2011.10.004

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  15 in total

1.  Reconceptualizing Triage to Incorporate Principles of Risk and Uncertainty: An Example from Deep Brain Stimulation Patients with Treatment-Resistant Disorders.

Authors:  Lavina Kalwani; Kristin Kostick; Eric A Storch; Gabriel Lázaro-Muñoz
Journal:  Am J Bioeth       Date:  2020-07       Impact factor: 11.229

Review 2.  Neuromodulation for obsessive-compulsive disorder.

Authors:  Kyle A B Lapidus; Emily R Stern; Heather A Berlin; Wayne K Goodman
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

Review 3.  Improving long term patient outcomes from deep brain stimulation for treatment-refractory obsessive-compulsive disorder.

Authors:  Andrew Guzick; Patrick J Hunt; Kelly R Bijanki; Sophie C Schneider; Sameer A Sheth; Wayne K Goodman; Eric A Storch
Journal:  Expert Rev Neurother       Date:  2019-11-22       Impact factor: 4.618

Review 4.  Disease-specific longevity of impulse generators in deep brain stimulation and review of the literature.

Authors:  Christoph van Riesen; Georg Tsironis; Doreen Gruber; Fabian Klostermann; Patricia Krause; Gerd Helge Schneider; Andreas Kupsch
Journal:  J Neural Transm (Vienna)       Date:  2016-05-19       Impact factor: 3.575

5.  Charting the road forward in psychiatric neurosurgery: proceedings of the 2016 American Society for Stereotactic and Functional Neurosurgery workshop on neuromodulation for psychiatric disorders.

Authors:  Ausaf A Bari; Charles B Mikell; Aviva Abosch; Sharona Ben-Haim; Robert J Buchanan; Allen W Burton; Stephen Carcieri; G Rees Cosgrove; Pierre-Francois D'Haese; Zafiris Jeffrey Daskalakis; Emad N Eskandar; Jason L Gerrard; Wayne K Goodman; Benjamin David Greenberg; Robert E Gross; Clement Hamani; Zelma H T Kiss; Peter Konrad; Brian H Kopell; Lothar Krinke; Jean-Philippe Langevin; Andres M Lozano; Donald Malone; Helen S Mayberg; Jonathan P Miller; Parag G Patil; DeLea Peichel; Erika A Petersen; Ali R Rezai; R Mark Richardson; Patricio Riva-Posse; Tejas Sankar; Jason M Schwalb; Helen Blair Simpson; Konstantin Slavin; Paul H Stypulkowski; Tor Tosteson; Peter Warnke; Jon T Willie; Kareem A Zaghloul; Joseph S Neimat; Nader Pouratian; Sameer A Sheth
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-01-25       Impact factor: 10.154

6.  Long-term high frequency deep brain stimulation of the nucleus accumbens drives time-dependent changes in functional connectivity in the rodent limbic system.

Authors:  Samuel G Ewing; Anthony A Grace
Journal:  Brain Stimul       Date:  2012-08-23       Impact factor: 8.955

7.  Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are modulated by psychiatric diagnosis.

Authors:  Sarah A Eisenstein; William B Dewispelaere; Meghan C Campbell; Heather M Lugar; Joel S Perlmutter; Kevin J Black; Tamara Hershey
Journal:  Brain Stimul       Date:  2014-06-12       Impact factor: 8.955

8.  Target-specific deep brain stimulation of the ventral capsule/ventral striatum for the treatment of neuropsychiatric disease.

Authors:  Chencheng Zhang; Dianyou Li; Haiyan Jin; Kristina Zeljic; Bomin Sun
Journal:  Ann Transl Med       Date:  2017-10

9.  Management of deep brain stimulator battery failure: battery estimators, charge density, and importance of clinical symptoms.

Authors:  Kaihan Fakhar; Erin Hastings; Christopher R Butson; Kelly D Foote; Pam Zeilman; Michael S Okun
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

10.  Deep brain stimulation for treatment-refractory obsessive compulsive disorder: a systematic review.

Authors:  Sina Kohl; Deva M Schönherr; Judy Luigjes; Damiaan Denys; Ulf J Mueller; Doris Lenartz; Veerle Visser-Vandewalle; Jens Kuhn
Journal:  BMC Psychiatry       Date:  2014-08-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.